ARVN Stock Summary and Trading Ideas (Arvinas | NASDAQ:ARVN)

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Arvinas trades on the NASDAQ stock market under the symbol ARVN.

As of November 7, 2024, ARVN stock price declined to $27.75 with 333,010 million shares trading.

ARVN has a beta of 1.57, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.07 to the broad based SPY ETF.

ARVN has a market cap of $1.90 billion. This is considered a Small Cap stock.

Last quarter Arvinas reported $102 million in Revenue and -$.68 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.28.

In the last 3 years, ARVN traded as high as $95.93 and as low as $13.57.

The top ETF exchange traded funds that ARVN belongs to (by Net Assets): IWM, VTI, VB, VXF, VBK.

ARVN has outperformed the market in the last year with a price return of +63.9% while the SPY ETF gained +38.3%. However, in the short term, ARVN had mixed performance relative to the market. It has underperformed in the last 3 months, returning +10.2% vs +14.4% return in SPY. But in the last 2 weeks, ARVN shares have fared better than the market returning +4.6% compared to SPY +3.0%.

ARVN support price is $26.95 and resistance is $29.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN shares will trade within this expected range on the day.